Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas

MPM (Malignant Pleural Mesothelioma) is an aggressive tumor with no effective therapy. However PD-L1/PD-1 immunity checkpoint therapies gave encouraging results; TLR3 is a programmed death factor, which triggering up-regulates PD-L1. As PD-1/PD-L1 blocking antibodies could restore antitumor immune responses alone or in combination with TLR3 agonists, we investigated PD-L1/PD-1 and TLR3 expressions in MPM to select patients for immunotherapy. Sixty-eight pleural surgical specimens, including 58 MPM (epithelioid; n= 34, biphasic; n=11, sarcomatoid; n= 13) and 10 benign lesions, were studied. (Source: Human Pathology)

from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=164986240&cid=c_409_32_f&fid=35623&url=http%3A%2F%2Fwww.humanpathol.com%2Farticle%2FS0046-8177%2816%2900042-3%2Fabstract%3Frss%3Dyes